APOE and Alzheimer disease: Further evidence of the improved AD risk prognostication was provided through a pilot study that demonstrated increased diagnostic accuracy for MCI and AD using a model incorporating a broad metabolomic panel (AUC = 0.95) compared to baseline models consisting of only age, sex and APOE ε4 status (AUC = 0.72–0.79) [186].